Abstract :
( Hodgkins LymphomaHL) was first described by Thomas Hodgkin in 1832., is a malignant disorder, a rare B cell lymphoma (mutant lymphocytes) with reasonable outcome due to the fair cure rates achieved by modern chemotherapy and/or radiotherapy. The incidence of HL is 2.6 cases per 100,000 people, accounts for 10% lymphoma cases. The Epstein–Barr virus (EBV) is detected in nearly 45% of HL patients Most of the affected patients are between ages 20 to 40 years. HL is uncommon in children < 5>
Keyword :
Hodgkin lymphoma, PD-1 inhibitor, Antibody-drug conjugate, Brentuximab, Immunotherapy, PET-adapted therapy, Allogeneic stem cell transplant